Terms: = Prostate cancer AND PALB2, ENSG00000083093, 79728 AND Treatment
34 results:
1. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
2. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.
Paulo P; Cardoso M; Brandão A; Pinto P; Falconi A; Pinheiro M; Cerveira N; Silva R; Santos C; Pinto C; Peixoto A; Maia S; Teixeira MR
Genes Chromosomes Cancer; 2023 Dec; 62(12):710-720. PubMed ID: 37436117
[TBL] [Abstract] [Full Text] [Related]
3. Rucaparib for the treatment of Metastatic Castration-resistant prostate cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
[TBL] [Abstract] [Full Text] [Related]
4. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract] [Full Text] [Related]
5. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic prostate cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
[TBL] [Abstract] [Full Text] [Related]
6. Germline genetics of prostate cancer.
Khan HM; Cheng HH
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S3-S12. PubMed ID: 35657157
[TBL] [Abstract] [Full Text] [Related]
7. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
8. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and palb2 in a Tumor-Only Genomic Testing Program.
Bychkovsky BL; Li T; Sotelo J; Tayob N; Mercado J; Gomy I; Chittenden A; Kane S; Stokes S; Hughes ME; Kim JS; Umeton R; Awad MM; Konstantinopoulos PA; Yurgelun MB; Wolpin BM; Taplin ME; Newmark RE; Johnson BE; Lindeman NI; MacConaill LE; Garber JE; Lin NU
Clin Cancer Res; 2022 Jun; 28(11):2349-2360. PubMed ID: 35363308
[TBL] [Abstract] [Full Text] [Related]
9. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
[TBL] [Abstract] [Full Text] [Related]
10. Germline palb2 Variants and PARP Inhibitors in Endometrial cancer.
Cilento MA; Poplawski NK; Paramasivam S; Thomas DM; Kichenadasse G
J Natl Compr Canc Netw; 2021 Nov; 19(11):1212-1217. PubMed ID: 34781271
[TBL] [Abstract] [Full Text] [Related]
11. Inherited Mutations in Chinese Men With prostate cancer.
Zhu Y; Wei Y; Zeng H; Li Y; Ng CF; Zhou F; He C; Sun G; Ni Y; Chiu PKF; Teoh JYC; Wang B; Pan J; Wan F; Dai B; Qin X; Lin G; Gan H; Wu J; Ye D
J Natl Compr Canc Netw; 2021 Oct; 20(1):54-62. PubMed ID: 34653963
[TBL] [Abstract] [Full Text] [Related]
12. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract] [Full Text] [Related]
13. Genetically Informed prostate cancer treatment for Metastatic Disease.
Siebert AL; Szymaniak BM; Numan Y; Morgans AK
Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
[TBL] [Abstract] [Full Text] [Related]
14. Therapeutic Implications of Germline Testing in Patients With Advanced cancers.
Stadler ZK; Maio A; Chakravarty D; Kemel Y; Sheehan M; Salo-Mullen E; Tkachuk K; Fong CJ; Nguyen B; Erakky A; Cadoo K; Liu Y; Carlo MI; Latham A; Zhang H; Kundra R; Smith S; Galle J; Aghajanian C; Abu-Rustum N; Varghese A; O'Reilly EM; Morris M; Abida W; Walsh M; Drilon A; Jayakumaran G; Zehir A; Ladanyi M; Ceyhan-Birsoy O; Solit DB; Schultz N; Berger MF; Mandelker D; Diaz LA; Offit K; Robson ME
J Clin Oncol; 2021 Aug; 39(24):2698-2709. PubMed ID: 34133209
[TBL] [Abstract] [Full Text] [Related]
15. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
Shore N; Ionescu-Ittu R; Yang L; Laliberté F; Mahendran M; Lejeune D; Yu L; Burgents J; Duh MS; Ghate SR
Future Oncol; 2021 Aug; 17(22):2907-2921. PubMed ID: 33906368
[TBL] [Abstract] [Full Text] [Related]
16. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
[TBL] [Abstract] [Full Text] [Related]
17. Pan-cancer landscape of homologous recombination deficiency.
Nguyen L; W M Martens J; Van Hoeck A; Cuppen E
Nat Commun; 2020 Nov; 11(1):5584. PubMed ID: 33149131
[TBL] [Abstract] [Full Text] [Related]
18. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Varnai R; Sipeky C
Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
[TBL] [Abstract] [Full Text] [Related]
19. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of a Mainstream Model of Genetic Testing for Men With prostate cancer.
Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler MR; Strach MC; Tran B; Young AL; Zhang AY; Mahon KL; Horvath LG
JCO Oncol Pract; 2021 Feb; 17(2):e204-e216. PubMed ID: 32970524
[TBL] [Abstract] [Full Text] [Related]
[Next]